Table 2.

Adverse events

	Grades 1–2	Grade 3
Laboratory
Thrombocytopaenia	6 (8%)	2
Hyperbilirubinaemia	7 (9%)	0
ALT increase	2 (3%)	0
Anaemia	2 (3%)	0
Neutropenia	2 (3%)	0
Metabolic and nutritional
Anorexia	4 (5%)	0
Fatigue	14 (18%)	0
Dermatological
Conjunctivitis	1 (1%)	0
Dermatitis	5 (6%)	0
Pruritus	6 (8%)	0
Gastrointestinal
Abdominal pain	2 (3%)	0
Diarrhoea	2 (3%)	0
Nausea/Vomiting	6 (8%)	0
Pain
Muscular pain	6 (8%)	0
Nervous
Dysgeusia	3 (4%)	0
Limbs paraesthesia	1 (1%)	0
Bleeding
Epistaxis	3 (4%)	0
Respiratory
Cough	2 (3%)	0
Fever
Fever	2 (3%)	0
Cardiovascular
Hypertension	1 (1%)	0

Data are n (%). Treatment-related adverse events are reported if they occurred in at least 1% of patients or were of Common Terminology Criteria for Adverse Events grade 3 or worse. All patients who received at least one dose of drug are included (n=31). No grade 4 or 5 adverse events occurred.

ALT, alanine aminotransferase.